Michael R. Bristow

57.8k total citations · 11 hit papers
403 papers, 40.5k citations indexed

About

Michael R. Bristow is a scholar working on Cardiology and Cardiovascular Medicine, Molecular Biology and Surgery. According to data from OpenAlex, Michael R. Bristow has authored 403 papers receiving a total of 40.5k indexed citations (citations by other indexed papers that have themselves been cited), including 268 papers in Cardiology and Cardiovascular Medicine, 145 papers in Molecular Biology and 58 papers in Surgery. Recurrent topics in Michael R. Bristow's work include Heart Failure Treatment and Management (111 papers), Cardiac electrophysiology and arrhythmias (93 papers) and Receptor Mechanisms and Signaling (80 papers). Michael R. Bristow is often cited by papers focused on Heart Failure Treatment and Management (111 papers), Cardiac electrophysiology and arrhythmias (93 papers) and Receptor Mechanisms and Signaling (80 papers). Michael R. Bristow collaborates with scholars based in United States, Italy and Canada. Michael R. Bristow's co-authors include Edward M. Gilbert, Wayne Minobe, Michael B. Fowler, Arthur M. Feldman, Robert Ginsburg, Wilson S. Colucci, Jay N. Cohn, Milton Packer, Neil H. Shusterman and J. David Port and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Michael R. Bristow

393 papers receiving 38.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cardiac-Resynchronization Therapy with or without an Implantable Defibrillator in Advanced Chronic Heart Failure

2004 4.0k citations Michael R. Bristow, Leslie A. Saxon et al. profile →
The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure

1996 3.4k citations Michael R. Bristow, Wilson S. Colucci et al. profile →
Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies

1996 2.5k citations Michael R. Bristow et al. Circulation profile →
Decreased Catecholamine Sensitivity and β-Adrenergic-Receptor Density in Failing Human Hearts

1982 1.8k citations Michael R. Bristow, Robert Ginsburg et al. profile →
Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure.

1986 1.0k citations Michael R. Bristow, Robert Ginsburg et al. Circulation Research profile →
Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy

1993 902 citations Michael R. Bristow, Edward M. Gilbert et al. The Lancet profile →
β-Adrenergic Receptor Blockade in Chronic Heart Failure

2000 783 citations Michael R. Bristow Circulation profile →
Mechanisms and Models in Heart Failure

2005 626 citations Michael R. Bristow et al. Circulation profile →
Economic impact of heart failure in the United States: time for a different approach.

1994 517 citations Michael R. Bristow et al. profile →
Assessment of the beta-adrenergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and subsensitivity to agonist response.

1986 431 citations Wayne Minobe, Michael R. Bristow et al. Circulation profile →
COVID-19 and Cardiovascular Disease

2021 251 citations Mina K. Chung, David A. Zidar et al. Circulation Research profile →

Peers

Countries citing papers authored by Michael R. Bristow

Since Specialization

Citations

This map shows the geographic impact of Michael R. Bristow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael R. Bristow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael R. Bristow more than expected).

Fields of papers citing papers by Michael R. Bristow

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael R. Bristow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael R. Bristow. The network helps show where Michael R. Bristow may publish in the future.

Co-authorship network of co-authors of Michael R. Bristow

This figure shows the co-authorship network connecting the top 25 collaborators of Michael R. Bristow. A scholar is included among the top collaborators of Michael R. Bristow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael R. Bristow. Michael R. Bristow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	METTL3 Is Essential for Exercise Benefits in Diabetic Cardiomyopathy 2025 ·Circulation ·Chunyan Wang, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Zipeng Liu, Tina B. McKay, Oluwaseun Akeju, (unknown), Amrut V. Ambardekar, Michael R. Bristow, Weifeng Yao, Haobo Li	3
2	Vaccination-Associated Myocarditis and Myocardial Injury 2023 ·Circulation Research ·Natasha Altman, (unknown), Sarah Mann, Robert A. Quaife, Edward A. Gill, Scott R. Auerbach, Thomas Campbell, Michael R. Bristow	18
3	Dysregulated Autophagy and Sarcomere Dysfunction in Patients With Heart Failure With Co‐Occurrence of P63A and P380S BAG3 Variants 2023 ·Journal of the American Heart Association ·Thomas G. Martin, (unknown), Glenn S. Gerhard, Salim Merali, Carmen Merali, Bonnie Lemster, Praveen Kumar Dubey, Charles F. McTiernan, Michael R. Bristow, Arthur M. Feldman, Jonathan A. Kirk	2
4	Inhibition of Eicosanoid Degradation Mitigates Fibrosis of the Heart 2022 ·Circulation Research ·Marcello Rubino, Joshua G. Travers, (unknown), (unknown), Madeleine E. Lemieux, Maria A. Cavasin, (unknown), (unknown), (unknown), Marina Barreto Felisbino, (unknown), Amrut V. Ambardekar, Michael R. Bristow, Keith A. Koch, Timothy A. McKinsey	14
5	Myocardial Injury and Altered Gene Expression Associated With SARS-CoV-2 Infection or mRNA Vaccination 2022 ·JACC Basic to Translational Science ·Natasha Altman, (unknown), (unknown), (unknown), (unknown), Dobromir Slavov, Robert A. Quaife, Edward A. Gill, Wayne Minobe, (unknown), (unknown), (unknown), (unknown), John C. Messenger, Amrut V. Ambardekar, Luisa Mestroni, (unknown), Jessica Y. Rove, Thomas Campbell, Michael R. Bristow	11
6	Heart Failure Strategically Focused Research Network: Summary of Results and Future Directions 2022 ·Journal of the American Heart Association ·G. Michael Felker, Peter M. Buttrick, Anthony Rosenzweig, E. Dale Abel, Larry A. Allen, Michael R. Bristow, Saumya Das, Adam D. DeVore, Stavros G. Drakos, James C. Fang, Jane E. Freedman, Adrian F. Hernandez, Dean Y. Li, Timothy A. McKinsey, Christopher Newton‐Cheh, Joseph G. Rogers, Ravi V. Shah, Svati H. Shah, Josef Stehlik, Craig H. Selzman	2
7	COVID-19 and Cardiovascular Disease breakdown → 2021 ·Circulation Research ·Mina K. Chung, David A. Zidar, Michael R. Bristow, Scott J. Cameron, Timothy A. Chan, Clifford V. Harding, Deborah Kwon, Tamanna Singh, John C. Tilton, Emily J. Tsai, Nathan R. Tucker, John Barnard, Joseph Loscalzo	251
8	Sequential analysis of myocardial gene expression with phenotypic change: Use of cross-platform concordance to strengthen biologic relevance 2019 ·PLoS ONE ·(unknown), (unknown), Kenneth L. Jones, (unknown), Wayne Minobe, Erin M. Rodríguez, Natasha Altman, Brian D. Lowes, Edward M. Gilbert, Peter M. Buttrick, David Kao, Michael R. Bristow	8
9	Histamine H2 Receptor Polymorphisms, Myocardial Transcripts, and Heart Failure (from the Multi-Ethnic Study of Atherosclerosis and Beta-Blocker Effect on Remodeling and Gene Expression Trial) 2017 ·The American Journal of Cardiology ·Peter J. Leary, Richard A. Kronmal, David A. Bluemke, Peter M. Buttrick, Kenneth L. Jones, David Kao, Steven M. Kawut, Eric V. Krieger, João A.C. Lima, Wayne Minobe, David Ralph, Ryan J. Tedford, Noel S. Weiss, Michael R. Bristow	14
10	Effects of Cardiac Resynchronization Therapy With or Without a Defibrillator on Survival and Hospitalizations in Patients With New York Heart Association Class IV Heart Failure 2006 ·Circulation ·JoAnn Lindenfeld, Arthur M. Feldman, Leslie A. Saxon, John Boehmer, Peter E. Carson, Jalal K. Ghali, Inder S. Anand, (unknown), Jonathan S. Steinberg, Brian E. Jaski, Teresa DeMarco, David Mann, Patrick Yong, Elizabeth Galle, Fred Ecklund, Michael R. Bristow	142
11	Alterations in cAMP‐Mediated Signaling and Their Role in the Pathophysiology of Dilated Cardiomyopathy 2005 ·Current topics in developmental biology ·Matthew A. Movsesian, Michael R. Bristow	53
12	Peak oxygen consumption and outcome in heart failure patients chronically treated with β-blockers 2004 ·Journal of Cardiac Failure ·Simon F. Shakar, Brian D. Lowes, JoAnn Lindenfeld, R. Zolty, (unknown), (unknown), Michael R. Bristow, (unknown)	21
13	Signaling Pathways Responsible for Fetal Gene Expression in the Failing Human Heart- Evidence for Altered Thyroid Hormone Receptor Gene Expression 2003 ·Japanese Circulation Journal-english Edition ·Koichiro Kinugawa, Mark Y. Jeong, Atsushi Yao, Toshiyuki Takahashi, Ryozo Nagai, Carlin S. Long, Michael R. Bristow	1
14	Reciprocal modulation of mitogen-activated protein kinases and mitogen-activated protein kinase phosphatase 1 and 2 in failing human myocardium 2002 ·Journal of Cardiac Failure ·Catherine Communal, Wilson S. Colucci, Andréa Remondino, Douglas B. Sawyer, J. David Port, (unknown), Michael R. Bristow, Krishna Singh	41
15	Combined Oral Positive Inotropic and Beta-Blocker Therapy for Treatment of Refractory Class IV Heart Failure 1998 ·Journal of the American College of Cardiology ·Simon F. Shakar, William T. Abraham, Edward M. Gilbert, A. Robertson, Brian D. Lowes, Lawrence S. Zisman, Debra A. Ferguson, Michael R. Bristow	102
16	Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy 1993 ·The Lancet ·M V Raynolds, Michael R. Bristow, E.W. Bush, William T. Abraham, Brian D. Lowes, Lawrence S. Zisman, Charles Taft, M. Benjamin Perryman	351
17	Effect of Therapeutic Dopamine Administration on Myocardial Catecholamine and Neuropeptide Y Concentrations in the Failing Ventricles of Patients with Idiopathic Dilated Cardiomyopathy 1992 ·Journal of Cardiovascular Pharmacology ·Fred Anderson, J. David Port, B.B. Reid, Glen R. Hanson, (unknown), Ray E. Hershberger, Michael R. Bristow	1
18	Prevention of cardiovascular events in variant angina by long-term diltiazem therapy 1983 ·Journal of the American College of Cardiology ·John S. Schroeder, Irene H. Lamb, Michael R. Bristow, Robert Ginsburg, Joseph Hung, Bruce J. McAuley	28
19	Vascular H1-receptor up-regulation in rabbits fed a high cholesterol diet 1981 ·Arteriosclerosis An Official Journal of the American Heart Association Inc ·Keith G. Lurie, Michael R. Bristow, Robert Ginsburg	3
20	Proceedings of the British Cardiac Society 1979 ·Heart ·Graham Jackson, Robert E. Bowden, Robert Ginsburg, Michael R. Bristow, Donald C. Harrison, Vijay Balasubramanian, E. B. Raftery, Avijit Lahiri, David M. Kaye, F. D. Stott, Helene von Bibra, D G Gibson, (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact